Mitragynine: receptor binding, metabolism, and dose-response

Scope and caveats

This page synthesises peer-reviewed work on the molecular and clinical pharmacology of mitragynine. It is a literature summary, not novel research. Each claim references a primary source listed at the bottom of the page; the linked papers themselves are the authoritative record.

Where evidence is thin, conflicting, or limited to preclinical models, the text says so explicitly. Pharmacology research on kratom expanded significantly after 2014; older results are often refined or superseded by more recent work.

Receptor pharmacology

Mitragynine acts at multiple receptor systems. Best characterised: partial μ-opioid receptor agonism, with interactions also documented at α₂-adrenergic and δ-/κ-opioid receptors.^[1,2]Mitragynine's μ-opioid affinity is substantially weaker than that of its metabolite 7-hydroxymitragynine; functional effects observed in animal models often track 7-OH plasma exposure rather than mitragynine itself.^[1]

Beyond the opioid system, Obeng et al. (2020) reported measurable α₂-adrenergic activity for several indole-based kratom alkaloids, including mitragynine.^[2]The clinical significance of the adrenergic component remains an open question; it has been proposed as one explanation for mitragynine's reported stimulant-like effects at lower doses.

Metabolism

Mitragynine undergoes hepatic metabolism, with CYP3A4 implicated as a primary metabolic pathway. A clinical interaction study with the CYP3A inhibitor itraconazole reported elevated mitragynine and 7-hydroxymitragynine plasma levels, consistent with CYP3A involvement in clearance.^[5]

7-Hydroxymitragynine is generated as a metabolite of mitragynine in vivo. The proportion of 7-OH formed from mitragynine metabolism, relative to that already present in the leaf, has been a subject of multiple studies; the body of evidence supports the view that systemic 7-OH exposure after oral kratom comes from a mixture of preformed and metabolised pools.^[1,2]

Human pharmacokinetics

Trakulsrichai et al. (2015) reported the first published human pharmacokinetic study of mitragynine, in chronic kratom users. The terminal elimination half-life was approximately one day, and the kinetics were linear across the doses tested. Unchanged mitragynine in urine was a small fraction of the dose, consistent with extensive metabolic clearance.^[3]

Huestis et al. (2024) reported the largest controlled human pharmacokinetic study to date — a randomized, double-blind, placebo-controlled, dose-escalation trial of oral encapsulated dried kratom leaf at 500–4000 mg per dose. Both mitragynine and 7-hydroxymitragynine showed dose-proportional C_max, peak plasma concentrations 1–2 hours after administration, and longer elimination half-lives during repeated dosing than after single doses, with steady state reached within 7–9 days of daily dosing.^[4]

Open questions

• ·The relative contributions of mitragynine and 7-OH to the clinical effects observed in human users — particularly whether the partial μ-opioid agonism of mitragynine alone accounts for the reported stimulant-at-low-dose, analgesic-at-high-dose pattern.
• ·Drug-drug interactions through CYP3A4 and other hepatic pathways. The itraconazole study established the principle; full mapping across commonly co-administered medications has not been published.^[5]
• ·Inter-individual variability in mitragynine PK — reported in both Trakulsrichai and Huestis studies — and its clinical implications for dose-response.^[3,4]